235 related articles for article (PubMed ID: 31907720)
1. Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice.
Tamura D; Jinnouchi N; Abe M; Ikarashi D; Matsuura T; Kato R; Maekawa S; Kato Y; Kanehira M; Takata R; Obara W
Int J Clin Oncol; 2020 May; 25(5):899-905. PubMed ID: 31907720
[TBL] [Abstract][Full Text] [Related]
2. Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab.
Kobayashi T; Ito K; Kojima T; Kato M; Kanda S; Hatakeyama S; Matsui Y; Matsushita Y; Naito S; Shiga M; Miyake M; Muro Y; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Taoka R; Kamiyama M; Ogawa O; Kitamura H; Nishiyama H;
Cancer Sci; 2021 Feb; 112(2):760-773. PubMed ID: 33283385
[TBL] [Abstract][Full Text] [Related]
3. Initial Experience of Pembrolizumab Therapy in Japanese Patients With Metastatic Urothelial Cancer.
Yasuoka S; Yuasa T; Nishimura N; Ogawa M; Komai Y; Numao N; Yamamoto S; Kondo Y; Yonese J
Anticancer Res; 2019 Jul; 39(7):3887-3892. PubMed ID: 31262917
[TBL] [Abstract][Full Text] [Related]
4. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
[TBL] [Abstract][Full Text] [Related]
5. Association of Immune-Related Adverse Events with Pembrolizumab Efficacy in the Treatment of Advanced Urothelial Carcinoma.
Kobayashi K; Suzuki K; Hiraide M; Aoyama T; Yokokawa T; Shikibu S; Hashimoto K; Iikura Y; Sato H; Sugiyama E; Tajima M; Hama T
Oncology; 2020; 98(4):237-242. PubMed ID: 31935736
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort.
Ito K; Kobayashi T; Kojima T; Hikami K; Yamada T; Ogawa K; Nakamura K; Sassa N; Yokomizo A; Abe T; Tsuchihashi K; Tatarano S; Inokuchi J; Tomida R; Fujiwara M; Takahashi A; Matsumoto K; Shimizu K; Araki H; Kurahashi R; Osaki Y; Tashiro Y; Uegaki M; Ogawa O; Kitamura H; Nishiyama H
Cancer Med; 2021 May; 10(10):3188-3196. PubMed ID: 33931987
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status.
Grivas P; Plimack ER; Balar AV; Castellano D; O'Donnell PH; Bellmunt J; Powles T; Hahn NM; de Wit R; Bajorin DF; Ellison MC; Frenkl TL; Godwin JL; Vuky J
Eur Urol Oncol; 2020 Jun; 3(3):351-359. PubMed ID: 32423837
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab in the treatment of advanced urothelial cancer.
Lundgren KT; Farina MS; Bellmunt J
Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
[TBL] [Abstract][Full Text] [Related]
10. Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer.
Galsky MD; Mortazavi A; Milowsky MI; George S; Gupta S; Fleming MT; Dang LH; Geynisman DM; Walling R; Alter RS; Kassar M; Wang J; Gupta S; Davis N; Picus J; Philips G; Quinn DI; Haines GK; Hahn NM; Zhao Q; Yu M; Pal SK
J Clin Oncol; 2020 Jun; 38(16):1797-1806. PubMed ID: 32271672
[TBL] [Abstract][Full Text] [Related]
11. Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis.
Etani T; Naiki T; Sugiyama Y; Nagai T; Iida K; Noda Y; Shimizu N; Tasaki Y; Mimura Y; Okada T; Banno R; Kubota H; Hamamoto S; Ando R; Kawai N; Yasui T
Oncology; 2020; 98(12):876-883. PubMed ID: 32862183
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
Bellmunt J; de Wit R; Vaughn DJ; Fradet Y; Lee JL; Fong L; Vogelzang NJ; Climent MA; Petrylak DP; Choueiri TK; Necchi A; Gerritsen W; Gurney H; Quinn DI; Culine S; Sternberg CN; Mai Y; Poehlein CH; Perini RF; Bajorin DF;
N Engl J Med; 2017 Mar; 376(11):1015-1026. PubMed ID: 28212060
[TBL] [Abstract][Full Text] [Related]
13. Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR.
Kobayashi T; Ito K; Kojima T; Maruyama S; Mukai S; Tsutsumi M; Miki J; Okuno T; Yoshio Y; Matsumoto H; Shimazui T; Segawa T; Karashima T; Masui K; Fukuta F; Tashiro K; Imai K; Suekane S; Nagasawa S; Higashi S; Fukui T; Ogawa O; Kitamura H; Nishiyama H
Cancer Immunol Immunother; 2022 Feb; 71(2):461-471. PubMed ID: 34235546
[TBL] [Abstract][Full Text] [Related]
14. Blood Cell Count Biomarkers Predicting Efficacy of Pembrolizumab as Second-line Therapy for Advanced Urothelial Carcinoma.
Kadono Y; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kamijima T; Seto C; Takano A; Yotsuyanagi S; Nakagawa R; Miyagi T; Aoyama S; Asahi H; Fukuda R; Mizokami A
Anticancer Res; 2021 Mar; 41(3):1599-1606. PubMed ID: 33788755
[TBL] [Abstract][Full Text] [Related]
15. The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients.
Ogihara K; Kikuchi E; Shigeta K; Okabe T; Hattori S; Yamashita R; Yoshimine S; Shirotake S; Nakazawa R; Matsumoto K; Mizuno R; Hara S; Oyama M; Masuda T; Niwakawa M; Oya M
Urol Oncol; 2020 Jun; 38(6):602.e1-602.e10. PubMed ID: 32139290
[TBL] [Abstract][Full Text] [Related]
16. Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab.
Kijima T; Yamamoto H; Saito K; Kusuhara S; Yoshida S; Yokoyama M; Matsuoka Y; Numao N; Sakai Y; Matsubara N; Yuasa T; Masuda H; Yonese J; Kageyama Y; Fujii Y
Cancer Immunol Immunother; 2021 Mar; 70(3):657-665. PubMed ID: 32876736
[TBL] [Abstract][Full Text] [Related]
17. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.
Plimack ER; Bellmunt J; Gupta S; Berger R; Chow LQ; Juco J; Lunceford J; Saraf S; Perini RF; O'Donnell PH
Lancet Oncol; 2017 Feb; 18(2):212-220. PubMed ID: 28081914
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab as second-line treatment for urothelial cancer.
Mitchell F
Lancet Oncol; 2017 Apr; 18(4):e197. PubMed ID: 28238595
[No Abstract] [Full Text] [Related]
19. Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
Shindo T; Hashimoto K; Takahashi A; Miyamoto S; Kunishima Y; Sato S; Fukuta F; Hiyama Y; Takayanagi A; Kato R; Wanifuchi A; Ueki Y; Okada M; Adachi H; Kobayashi KO; Tanaka T; Masumori N;
Anticancer Res; 2024 Mar; 44(3):1271-1279. PubMed ID: 38423657
[TBL] [Abstract][Full Text] [Related]
20. Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice.
Furubayashi N; Kuroiwa K; Tokuda N; Tomoda T; Morokuma F; Hori Y; Negishi T; Inoue T; Kumagai M; Nakamura M
J Clin Med Res; 2020 May; 12(5):300-306. PubMed ID: 32489505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
